奥精医疗(688613.SH)公告，公司于2024年8月向国家药监局递交了公司可吸收复合骨修复材料医疗器械 产品的注册申报资料。公司于近日收到国家药监局通知，公司可吸收复合骨修复材料医疗器械产品获得 批准。 ...

智通财经APP讯，奥精医疗(688613.SH)公告，公司于2024年8月向国家药监局递交了公司可吸收复合骨 修复材料医疗器械产品的注册申报资料。公司于近日收到国家药监局通知，公司可吸收复合骨修复材料 医疗器械产品获得批准。 ...

本次获得可吸收复合骨修复材料医疗器械产品是在现有产品技术（人工骨修复材料，注册证号： 20193131531）的基础上，引入可吸收聚酯材料，在具有前代产品优良的生物相容性及促进骨愈合能力 的前提下，进一步增加了材料强度，并增强了材料降解可控性，能够更好的满足临床中不同条件下的骨 缺损修复。奥精医疗拥有可吸收复合骨修复材料医疗器械产品的完全自主知识产权，产品关键技术是骨 修复材料领域的重大进展，是生物材料领域的原始创新，开辟了一条自主制备生物材料的新途径，达到 国际领先水平。 格隆汇9月28日丨奥精医疗(688613.SH)公布，公司于2024年8月向国家药监局递交了公司可吸收复合骨 修复材料医疗器械产品的注册申报资料。公司于近日收到国家药监局通知，公司可吸收复合骨修复材料 医疗器械产品获得批准。 ...

Core Viewpoint - The company, AoJing Medical, has received approval from the National Medical Products Administration for its absorbable composite bone repair material medical device, marking a significant advancement in the field of biomaterials [1] Group 1: Product Development - The company submitted the registration application for the absorbable composite bone repair material medical device in August 2024 [1] - The new product builds on existing technology (artificial bone repair material, registration number: 20193131531) by incorporating absorbable polyester materials [1] - The new material enhances strength and controllable degradation while maintaining excellent biocompatibility and bone healing promotion capabilities [1] Group 2: Intellectual Property and Innovation - AoJing Medical holds complete independent intellectual property rights for the absorbable composite bone repair material medical device [1] - The key technology of this product represents a major breakthrough in the field of bone repair materials and is considered original innovation in biomaterials [1] - This development opens a new pathway for the independent preparation of biomaterials, achieving an internationally leading level [1]